Just Published: "Sri Lanka Pharmaceuticals & Healthcare Report Q1 2015"

From: Fast Market Research, Inc.
Published: Fri Jan 30 2015

Sri Lanka's improvements in healthcare have created stronger commercial opportunities for drugmakers in the country, which is also experiencing an epidemiological shift towards chronic diseases. However, strong reliance on foreign aid as well as medicine price caps will limit inc reases in revenue- earning opportunities.

Headline Expenditure Projections

* Pharmaceuticals: LKR67.70bn (USD524mn) in 2013, to LKR75.09bn (USD570mn) in 2014; +10.9% in local currency terms and 8.9% in US dollar terms over the five-year forecast period.
* Healthcare: LKR261.04bn (USD2.02bn) in 2013, to LKR283.97bn (USD2.16bn) in 2014; +8.8% in local currency terms and 6.8% in US dollar terms.

Risk/Reward Index

Sri Lanka's Pharmaceutical Risk/Reward Index (RRI) score for Q115 stands at 38.2 out of 100, making it the seventeenth-most attractive pharmaceutical market in the Asia Pacific region.

Full Report Details at
- http://www.fastmr.com/prod/951115_sri_lanka_pharmaceuticals_healthcare_report_q1.aspx?afid=301

Key Trends And Developments

* In October 2014, the Malaria Elimination Group signed the Colombo Declaration on Eliminating Malaria to affirm the group's continued assistance to Sri Lanka. This comes as the country celebrates the absence of local malaria cases since October 2012.
* In September 2014, the Sri Lankan health ministry disclosed that 25% of the country's population is diabetic. The disease also affects children, with 10% of school children in the country suffering from the disease and another 15% at risk according to a statement from the health ministry.
* In August 2014, by the Government Medical Officers Association found that 26.4% of private dispensary doctors lack proper qualifications, with 35% of doctors in the town of Gampaha unqualified to treat patients.

BMI Economic View: The Central Bank of Sri Lanka (CBSL) will keep its standing lending facility and deposit rates on hold at 8.00% and 6.50% respectively over 2014 and 2015, choosing to employ other measures to boost credit growth amid a growth-inflation sweet spot. That said, the central bank has room to cut...

The Sri Lanka Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Sri Lanka Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Sri Lanka pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Sri Lanka, to test other views - a key input for successful budgeting and strategic business planning in the Sri Lankan pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q1 2015
- Egypt Pharmaceuticals & Healthcare Report Q1 2015
- Vietnam Pharmaceuticals & Healthcare Report Q1 2015
- United Arab Emirates Pharmaceuticals & Healthcare Report Q1 2015
- Peru Pharmaceuticals & Healthcare Report Q1 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »